Zhejiang Anglikang Pharmaceutical Hits Day Low Amid Price Pressure at CNY 41.09

Zhejiang Anglikang Pharmaceutical Co. experienced significant activity on May 22, 2026, with the stock declining by 9.99% and reaching an intraday low of CNY 41.09. This mid-cap company, operating within the Pharmaceuticals & Biotechnology sector, has shown a mixed performance in recent periods. Over the past year, Zhejiang Anglikang has delivered an impressive return of 187.95%, significantly outperforming the China Shanghai Composite, which recorded a gain of 21.68%. However, the stock's recent performance has been less favorable, with a 4.95% decline over the past week. Financial metrics indicate that while the company has achieved a net profit growth of 172.44% for the nine months ending March 26, its long-term growth has been constrained, with net sales increasing at an annual rate of only 3.31% over the last five years. The stock currently has a price-to-book ratio of 4.87 and a return on equity of 9.35%. Despite the recent downturn, the company maintains a high dividend yield of 0.57%, reflecting its ongoing commitment to shareholder returns.